128940 — Hanmi Pharm Co Share Price
0.000.00%
Last trade - 00:00- KR₩3tn
- KR₩3tn
- KR₩1tn
- 64
- 26
- 26
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.83 | ||
| PEG Ratio (f) | 1.07 | ||
| EPS Growth (f) | 21.37% | ||
| Dividend Yield (f) | 0.33% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.81 | ||
| Price to Tang. Book | 3.08 | ||
| Price to Free Cashflow | 23.29 | ||
| Price to Sales | 2.04 | ||
| EV to EBITDA | 11.28 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.97% | ||
| Return on Equity | 11.89% | ||
| Operating Margin | 14.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 1,075,853.61 | 1,203,185.65 | 1,331,546.6 | 1,490,887.46 | 1,495,501.58 | 1,624,135 | 1,750,859 | 6.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -79.77 | +480.35 | +26.08 | +73.59 | -17.62 | +25.87 | +13.7 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hanmi Pharm Co Ltd is a Korea-based company principally engaged in the manufacturing and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceuticals segment manufactures and sells tablets, capsules, injections, syrups, powders and raw materials used in the treatment of hypertension, reflux esophagitis, influenza type A and influenza type B virus infections and hyperlipidemia, among others. The Other segment is engaged in the materials processing. The Export segment produces and sells products such as powders and injections, and exports technologies.
Directors
- Yeong Suk Song CMG (72)
- Seong Gi Yim CMG (81)
- Se Chang Gwon CPR (57)
- Jong Su Woo CPR (53)
- Jong Yun Yim CPR (48)
- Gwan Sun Lee VCH (61)
- Jong Hun Yim VPR (43)
- Ju Hyeon Yim VPR (46)
- Su Jin Kim MDR (53)
- Jae Hyeon Park MDR (52)
- Myeong Hui Park MDR (51)
- Gwi Hyeon Seo MDR (58)
- Seung Jae Baek OTH (45)
- Seong Ryong Cho OTH (42)
- Yin Yeong Choi OTH (49)
- Seon Jin Goh OTH (54)
- Gyu Chan Gwon OTH (50)
- Seong Pil Jin OTH (51)
- Jin Ah Jung OTH (50)
- Jeong Sik Kim OTH (46)
- Na Yeong Kim OTH (45)
- Yeong Hun Kim OTH (58)
- Yong Yil Kim OTH (41)
- Ju Won Lee OTH (41)
- Yeong Mi Lee OTH (54)
- Jung Hyeon Park OTH (55)
- Mun Hwa Park OTH (47)
- Gyeong Hui Seo OTH (50)
- Byeong Hui Yoon OTH (51)
- Seong Hun Kim NID (62)
- Dong Ho Lee NID (68)
- Dong Cheol Seo NID (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 5th, 2010
- Public Since
- July 30th, 2010
- No. of Shareholders
- 43,200
- No. of Employees
- 2,095
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 12,680,214
- Address
- 214, Muha-ro, Paltan-myeon, HWASEONG, 18536
- Web
- https://www.hanmi.co.kr/
- Phone
- +82 313505600
- Auditors
- Ernst & Young Han Young
Upcoming Events for 128940
Q1 2025 Hanmi Pharm Co Ltd Earnings Release
Q2 2025 Hanmi Pharm Co Ltd Earnings Release
Similar to 128940
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Hanmi Pharm Co share price?
As of Today at 21:01 UTC, shares in Hanmi Pharm Co are trading at KR₩240,500. This share price information is delayed by 15 minutes.
How has the Hanmi Pharm Co share price performed this year?
Shares in Hanmi Pharm Co last closed at KR₩240,500 and the price had moved by -22.58% over the past 365 days. In terms of relative price strength the Hanmi Pharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -21.7% over the past year.
What are the analyst and broker recommendations for Hanmi Pharm Co?
The overall consensus recommendation for Hanmi Pharm Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Hanmi Pharm Co dividend yield?
The Hanmi Pharm Co dividend yield is 0.52% based on the trailing twelve month period.
Does Hanmi Pharm Co pay a dividend?
Last year, Hanmi Pharm Co paid a total dividend of KR₩1,250, and it currently has a trailing dividend yield of 0.52%. We do not have any data on when Hanmi Pharm Co is to next pay dividends.
When does Hanmi Pharm Co next pay dividends?
We do not have data on when Hanmi Pharm Co is to next pay dividends. The historic dividend yield on Hanmi Pharm Co shares is currently 0.52%.
How do I buy Hanmi Pharm Co shares?
To buy shares in Hanmi Pharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hanmi Pharm Co?
As of the previous close price of KR₩240,500, shares in Hanmi Pharm Co had a market capitalisation of KR₩3tn.
Where are Hanmi Pharm Co shares listed?
Here are the trading details for Hanmi Pharm Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 128940
What kind of share is Hanmi Pharm Co?
Based on an overall assessment of its quality, value and momentum Hanmi Pharm Co is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hanmi Pharm Co share price forecast for 2025?
The analyst consensus target price for shares in Hanmi Pharm Co is KR₩354,849. That is 47.55% above the last closing price of KR₩240,500.
Analysts covering Hanmi Pharm Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩12,242 for the next financial year.
Find out moreWhat is the trend in the Hanmi Pharm Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hanmi Pharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -23.05%.
As of the last closing price of KR₩240,500, shares in Hanmi Pharm Co were trading -14.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hanmi Pharm Co PE Ratio?
The Hanmi Pharm Co PE ratio based on its reported earnings over the past 12 months is 18.83. The shares last closed at KR₩240,500.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hanmi Pharm Co?
Hanmi Pharm Co's management team is headed by:
- Yeong Suk Song - CMG
- Seong Gi Yim - CMG
- Se Chang Gwon - CPR
- Jong Su Woo - CPR
- Jong Yun Yim - CPR
- Gwan Sun Lee - VCH
- Jong Hun Yim - VPR
- Ju Hyeon Yim - VPR
- Su Jin Kim - MDR
- Jae Hyeon Park - MDR
- Myeong Hui Park - MDR
- Gwi Hyeon Seo - MDR
- Seung Jae Baek - OTH
- Seong Ryong Cho - OTH
- Yin Yeong Choi - OTH
- Seon Jin Goh - OTH
- Gyu Chan Gwon - OTH
- Seong Pil Jin - OTH
- Jin Ah Jung - OTH
- Jeong Sik Kim - OTH
- Na Yeong Kim - OTH
- Yeong Hun Kim - OTH
- Yong Yil Kim - OTH
- Ju Won Lee - OTH
- Yeong Mi Lee - OTH
- Jung Hyeon Park - OTH
- Mun Hwa Park - OTH
- Gyeong Hui Seo - OTH
- Byeong Hui Yoon - OTH
- Seong Hun Kim - NID
- Dong Ho Lee - NID
- Dong Cheol Seo - NID